Agios制药 AGIO 深 沪

Saudi Food And Drug Authority Approves Agios' PYRUKYND For Adults With Thalassemia

First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA's Breakthrough Medicines ProgramAgios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and

08-05 04:22

Agios Pharma’s PYRUKYND Approved by Saudi Authority

An update from Agios Pharma ( ($AGIO) ) is now available. Agios Pharmaceuticals...

08-05 02:18

Agios Pharmaceuticals shares are trading higher amid reports of Pyrukynd patient deaths.

Agios Pharmaceuticals shares are trading higher amid reports of Pyrukynd patien...

08-04 23:33

Agios制药公司股价下跌，因报告指出Pyrukynd患者死亡

08-04 21:49

Agios製藥公司股價下跌，因報告指出Pyrukynd患者死亡案例

08-04 21:49

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals announced that the Saudi Food and Drug Authority (SFDA) has approved PYRUKYND® (mitapivat) for the treatment of adult patients with alpha- or beta-thalassemia. This marks the first regulatory approval for PYRUKYND in thalassemia under the SFDA’s Breakthrough Medicines Program. Agios partnered with NewBridge Pharmaceuticals to manage PYRUKYND’s commercialization in the Gulf Region. The approval is based on results from the Ph...

08-04 20:01

Agios Pharmaceuticals Q2 EPS $(1.93) Misses $(1.77) Estimate, Sales $12.455M Beat $9.537M Estimate

Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.93) per share which missed the analyst consensus estimate of $(1.77) by 8.73 percent. This is a 14.2 percent decrease over losses of $(1.69) per share

07-31 18:32

Earnings Scheduled For July 31, 2025

Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...

07-31 16:32

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update

Agios Pharmaceuticals reported second-quarter 2025 financial results, highlighting $12.5 million in net revenue for PYRUKYND® (mitapivat) and $1.3 billion in cash reserves. The company made progress on regulatory filings, including the sNDA for PYRUKYND in thalassemia with an FDA PDUFA date of September 7, 2025, and launched Phase 2 trials for tebapivat in sickle cell disease. R&D expenses increased to $91.9 million, reflecting advancements in th...

07-31 10:30

Here are the major earnings before the open Thursday

Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...

07-31 06:00